June 4, 2009 (FinancialWire) — Valeant Pharmaceuticals International (NYSE: VRX) has priced a private placement of $365 million of 8.375% senior notes due 2016. The principal amount was increased from a previously reported $300 million.

The senior notes were priced at 96.797% of the principal amount and will be issued by the company and unconditionally guaranteed by all of its domestic subsidiaries.

Valeant plans to use the net proceeds of this offering to repurchase securities and for general corporate purposes.

Aliso Viejo, California-based Valeant Pharmaceuticals is a specialty pharmaceutical company that develops and markets a range of pharmaceutical products primarily in the areas of neurology and dermatology.

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Free annual reports for companies mentioned in the news are available through the Free Annual Reports Service (http://investrend.ar.wilink.com/?level=279).

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.